Skip to main content
. 2022 Sep 12;14(18):4427. doi: 10.3390/cancers14184427

Figure 2.

Figure 2

Immunohistochemical status of the candidate survival risk stratification markers secreted protein acidic and rich in cysteine (SPARC), Human Epidermal Growth Factor Receptor 2 (HER2),inhibin subunit beta A (INHBA), matrix metallopeptidase 11 (MMP11), tumor protein P53 (TP53), and platelet-derived growth factor receptor-beta (PDGFRB), and galectin-10 identified by quantitative polymerase chain reaction (qPCR) and proteomic analysis. Representative images of high and low immunostaining of each candidate marker are shown.